On multivariate analysis, melanoma patients fared best as the hazard ratio (HR) for death was 3.1 (95% CI 1.7–5.9) for NSCLC and HR of 3.2 (95% CI 1.2–7.9) for RCC compared to melanoma (p = 0.0008) possibly due to improved responses to checkpoint inhibitors in melanoma with the incorporation of both PD-1 and CTLA-4 inhibitors into standard care. This evidence concerns the gene PDCD1 and renal cell carcinoma.